Bradley L. Pentelute
Bradley L. Pentelute | |
|---|---|
| Born | December 5, 1977 |
| Education | University of Southern California (USC) (B.A., Psychology, B.S., Chemistry)
University of Chicago (M.S., Chemistry, Ph.D., Organic Chemistry) Harvard Medical School (Fellowship) |
| Occupation | Professor of Chemistry at Massachusetts Institute of Technology(MIT) |
| Known for | Automated flow peptide synthesis
Pi-clamp bioconjugation mechanism Anthrax toxin delivery system Xenoprotein engineering Affinity selection-mass spectrometry |
| Awards | Collier Award
Damon Runyon-Rachleff Innovation Award Sontag Distinguished Scientist Award NSF CAREER Award Sloan Research Fellowship Amgen Young Investigator Award Eli Lilly Award |
| Website | http://www.pentelutelabmit.com/ |
Bradley Lether Pentelute (born December 5, 1977) is currently a professor of chemistry at the Massachusetts Institute of Technology (MIT). His research program lies at the intersection of chemistry and biology and develops bioconjugation strategies, cytosolic delivery platforms, and rapid flow synthesis technologies to optimize the production, achieve site-specific modification, enhance stability, and modulate function of a variety of bioactive agents. His laboratory successfully modified proteins via cysteine-containing “pi-clamps” made up of a short sequence of amino acids, and delivered large biomolecules, such as various proteins and drugs, into cells via the anthrax delivery vehicle. Pentelute has also made several key contributions to automated synthesis technologies in flow. These advances includes the invention of the world's fastest polypeptide synthesizer. This system is able to form amide bonds at a more efficient rate than standard commercial equipment and has helped in the process of understanding protein folding and its mechanisms. This automated flow technology was recently used to achieve total chemical synthesis of protein chains up to 164 amino acids in length that retained the structure and function of native variants obtained by recombinant expression. The primary goal of his endeavor is to use these processes to create designer biologics that can be used to treat diseases and solve the manufacturing problem for on-demand personalized therapies, such as cancer vaccines.